INTELLECTUAL PROPERTY/ LICENSING RIGHTS (Details Narrative) - USD ($) |
1 Months Ended | 12 Months Ended | ||||
---|---|---|---|---|---|---|
Aug. 20, 2018 |
Jul. 28, 2016 |
Jan. 26, 2016 |
Dec. 31, 2018 |
Dec. 31, 2017 |
Dec. 31, 2016 |
|
Intellectual property fees | $ 55,648 | |||||
Description for right to purchase perpetual rights | North America with the option for Central and South America for Naltrexone Implants formulas created by the Seller for 24 months upon receipt of the intellectual property for a fee of $55,648. The Company, within the first 12 months has the right to purchase perpetual rights for above territories for a one-time fee, financed over 5 years. The rights are amortized over the 24 month contract life. | |||||
Amortization expenses | $ 1,963 | $ 27,767 | ||||
Impairment loss | 250,000 | |||||
Carrying value | 0 | |||||
Naltrexone Implant Formulation [Member] | Australia from Trinity Compound Solutions [Member] | ||||||
Aggregate purchase price, value | $ 236,000 | |||||
Aggregate purchase price, Shares | 10,000 | |||||
Naltrexone Implant Formulation [Member] | New Zealand from Trinity Compound Solutions [Member] | ||||||
Aggregate purchase price, value | $ 236,000 | |||||
Aggregate purchase price, Shares | 20,000 | |||||
Therakine, Ltd. [Member] | ||||||
License cost | $ 2,750,000 | |||||
Aggregate purchase price, value | $ 250,000 | $ 250,000 | $ 250,000 | |||
Escrow deposit | $ 75,000 | |||||
Therakine, Ltd. [Member] | Minimum [Member] | ||||||
Milestone payments and royalties | 5.00% | |||||
Therakine, Ltd. [Member] | Maximum [Member] | ||||||
Milestone payments and royalties | 12.00% |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The designation of funds furnished by a borrower to a lender to assure future payments of the borrower's real estate taxes and insurance obligations with respect to a mortgaged property. Escrow deposits may be made for a variety of other purposes such as earnest money and contingent payments. This element excludes replacement reserves which are an escrow separately provided for within the US GAAP taxonomy. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The net cash inflow or outflow associated with the aggregate amount of adjustment to the purchase price of a previous acquisition. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|